Noloss ET 250mg/250mg Tablet

Noloss ET 250mg/250mg Tablet is a combination medicine used in the treatment of heavy menstrual bleeding. It works by preventing the breakdown of blood clots and controls excessive bleeding. It also increases the ability of platelets to stick together and form blood clots.

Noloss ET 250mg/250mg Tablet is given as an injection under the supervision of a doctor. Keep taking it for as long as advised by your doctor. Take this medicine in the dose and duration advised by the doctor and if you have missed a dose, take it as soon as you remember. Remember to finish the full course of treatment even if you feel better. It is important that this medication is not stopped suddenly without talking to the doctor.

The most common side effects of this medicine include nausea, stomach pain, headache, nasal congestion, sinus pain, sinus inflammation, rash, tiredness, and musculoskeletal (bone, muscle or joint) pain. It may also cause diarrhea, so it is better to take plenty of fluids while taking this medicine as it may help to prevent dehydration.

Before taking it, let your doctor know if you have any kidney problems or vaginal bleeding disorder. Pregnant or breastfeeding women should also consult their doctor for advice before taking this medicine. You also need to tell your doctor what other medicines you are taking. You might be asked for eye check-ups while taking this medicine.

• Heavy menstrual bleeding

Heavy menstrual bleeding
Noloss ET 250mg/250mg Tablet helps normal blood clotting, which reduces the bleeding during menstruation. It helps to prevent excessive loss of blood, stops bleeding and enhances the healing process. This helps prevent complications of excessive bleeding such as hemorrhage. If heavy periods become such a problem that they interfere with your everyday life, then try taking things a little easier on those days. Some women find that relaxation techniques or yoga help them feel more relaxed and reduce stress. Getting a lot of exercise can also help.

Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them

Common side effects of Emsyl

• Nausea
• Stomach pain
• Diarrhea
• Headache
• Nasal congestion (stuffy nose)
• Sinus pain
• Sinus inflammation
• Rash
• Tiredness
• Musculoskeletal (bone, muscle or joint) pain
• Anemia (low number of red blood cells)

Your doctor or nurse will give you this medicine. Kindly do not self administer.

Noloss ET 250mg/250mg Tablet is a combination of two medicines: Tranexamic Acid and Ethamsylate. Tranexamic Acid is an antifibrinolytic. It works by preventing the breakdown of blood clots and controls excessive bleeding. Ethamsylate is a hemostatic. It works by increasing the ability of platelets to stick together and form blood clots. It also helps control bleeding from tiny blood vessels (capillaries).

• Noloss ET 250mg/250mg Tablet is administered to reduce excessive bleeding during menstruation.
• Stick to simple meals and avoid spicy rich food in order to avoid feeling sick (nausea).
• If you get diarrhea while taking this medicine, consult your doctor immediately.
• Along with taking Noloss ET 250mg/250mg Tablet you can use a heating pad or try gentle massage and relaxation techniques to get relief during periods.
• Inform your doctor if there is no improvement in your bleeding after using this medicine for three consecutive periods.
• Inform your doctor if you have any bleeding disorders.

Tranexamic acid. London, UK: ADVANZ Pharma; 2013 [revised 5 Jul. 2018]. [Accessed 10 Apr. 2019] (online) Available from:

Garay PR, Chiavaroli C, Hannaert P. Therapeutic Efficacy and Mechanism of Action of Ethamsylate, a Long-Standing Hemostatic Agent. Am J Ther. 2006;13(3):236-47. [Accessed 10 Apr. 2019] (online) Available from:

Medscape. Tranexamic acid. [Accessed 10 Apr. 2019] (online) Available from:

Negrete R, Molina M, Gutierrez-Aceves J. Preoperative administration of ethamsylate: Reduces blood loss associated with percutaneous nepholithomy? A prospective randomized study. J Urol. 2009;181(4S):625. [Accessed 10 Apr. 2019] (online) Available from: